Artivion (NYSE:AORT) Announces Quarterly Earnings Results

by · The Cerbat Gem

Artivion (NYSE:AORT – Get Free Report) released its quarterly earnings data on Thursday. The company reported $0.13 EPS for the quarter, FiscalAI reports. Artivion had a positive return on equity of 6.07% and a negative net margin of 0.67%.The company had revenue of $125.76 million during the quarter, compared to the consensus estimate of $119.99 million.

Here are the key takeaways from Artivion’s conference call:

  • Q2 revenue increased 9% year over year to $125.8 million, while adjusted EBITDA rose 7% to $26.4 million. Stent graft revenue accelerated 12% and On-X revenue grew 18%, both despite tougher comparisons.
  • Artivion received FDA PMA approval for AMDS in June, removing IRB-related hurdles and expanding permitted marketing claims; management expects adoption and U.S. account conversions to accelerate gradually in the second half rather than through an immediate surge.
  • The company completed its Endospan acquisition and plans a full U.S. launch of the FDA-approved NEXUS aortic arch system in January 2027. Management views NEXUS, AMDS, On-X, and the ARTIZEN pipeline as collectively representing roughly $430 million in current U.S. market opportunity.
  • Artivion reiterated 2026 guidance for 7%–11% constant-currency revenue growth, or $480 million–$496 million, and adjusted EBITDA of $92 million–$99 million. The outlook assumes minimal NEXUS revenue this year, continued preservation-services timing and supply constraints, and roughly $8 million of Endospan-related expenses.
  • Free cash flow was negative $12 million in Q2, while net leverage rose to 3.1 following $150 million of borrowing to fund the Endospan acquisition; the company also expects the $25 million AMDS milestone payment in Q3 and remains exposed to manufacturing and geopolitical risks tied to Endospan’s Israel facility.

Artivion Stock Performance

Shares of NYSE AORT traded up $0.63 during midday trading on Friday, hitting $27.20. 1,081,660 shares of the company’s stock traded hands, compared to its average volume of 597,567. The firm has a fifty day moving average of $23.52 and a 200 day moving average of $31.13. Artivion has a 1 year low of $19.16 and a 1 year high of $48.25. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.80 and a current ratio of 3.86. The stock has a market capitalization of $1.32 billion, a price-to-earnings ratio of 49.20 and a beta of 1.25.

Key Headlines Impacting Artivion

Here are the key news stories impacting Artivion this week:

  • Positive Sentiment: Artivion reported second-quarter revenue of $125.8 million, up 11% year over year and above the approximately $120 million consensus estimate. Non-GAAP earnings were $0.13 per share, matching expectations, while adjusted EBITDA rose 7% to $26.4 million. Artivion Reports Second Quarter 2026 Financial Results
  • Positive Sentiment: The company received U.S. FDA PMA approval for its AMDS Hybrid Prosthesis, a regulatory milestone that could expand its aortic surgery product opportunity. Artivion also completed its acquisition of Endospan Ltd., potentially strengthening its portfolio and long-term growth prospects. Artivion Reports Second Quarter 2026 Financial Results
  • Positive Sentiment: Conestoga Capital Advisors highlighted Artivion as a long-term growth opportunity amid improving investor interest in small-cap stocks. The firm’s comments provide supportive institutional sentiment, although they do not represent a new price target or recommendation. Long-Term Growth Opportunities Remain for Artivion (AORT) Despite Challenges
  • Neutral Sentiment: Artivion maintained fiscal 2026 revenue guidance of $480 million to $496 million, a range broadly in line with the roughly $486.3 million analyst consensus. The earnings call offered further management commentary on the outlook and recent developments. Artivion Q2 2026 Earnings Call Transcript
  • Negative Sentiment: Despite the adjusted profit, Artivion posted a GAAP net loss of $13.5 million, or $0.28 per share, compared with $0.24 in earnings per share a year earlier. The company’s low 2.55% net margin and elevated valuation could make the stock sensitive to any execution or profitability concerns. Artivion Q2 Earnings Meet Estimates

Insider Activity

In related news, SVP Andrew M. Green sold 44,001 shares of the firm’s stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $20.70, for a total value of $910,820.70. Following the transaction, the senior vice president owned 60,259 shares of the company’s stock, valued at approximately $1,247,361.30. This trade represents a 42.20% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.30% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of AORT. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Artivion in the 3rd quarter worth $27,000. Smartleaf Asset Management LLC lifted its position in Artivion by 47.7% during the second quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company’s stock valued at $52,000 after purchasing an additional 538 shares in the last quarter. Kemnay Advisory Services Inc. purchased a new position in Artivion during the fourth quarter valued at $79,000. Quadrant Capital Group LLC bought a new stake in Artivion during the third quarter valued at about $92,000. Finally, iSAM Funds UK Ltd bought a new stake in Artivion during the third quarter valued at about $131,000. Hedge funds and other institutional investors own 86.37% of the company’s stock.

Analyst Ratings Changes

AORT has been the subject of a number of research analyst reports. Citigroup reiterated a “market outperform” rating on shares of Artivion in a research note on Tuesday, July 21st. Citizens Jmp dropped their target price on shares of Artivion from $53.00 to $48.00 and set a “market outperform” rating on the stock in a report on Friday, May 8th. Needham & Company LLC reaffirmed a “buy” rating and issued a $44.00 target price on shares of Artivion in a research report on Monday, July 20th. Weiss Ratings lowered shares of Artivion from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, June 8th. Finally, Wall Street Zen cut Artivion from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Artivion presently has a consensus rating of “Moderate Buy” and a consensus price target of $44.67.

View Our Latest Research Report on AORT

Artivion Company Profile

(Get Free Report)

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.

See Also